Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 4, 2012, Pages 673-684

  Kharasch, E D ^a   Whittington, D ^b   Ensign, D ^b   Hoffer, C ^b   Bedynek, P S ^b   Campbell, S ^a   Stubbert, K ^a   Crafford, A ^a   London, A ^a   Kim, T ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; EFAVIRENZ; FEXOFENADINE; METHADONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BEDTIME DOSAGE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED STUDY; DEMETHYLATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; HYDROXYLATION; LIVER CELL; LIVER CLEARANCE; MALE; MIOSIS; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEREOCHEMISTRY;

ADOLESCENT; ADULT; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; HEPATOCYTES; HUMANS; MALE; METHADONE; OXIDOREDUCTASES, N-DEMETHYLATING; YOUNG ADULT;

EID: 84862829066     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.276     Document Type: Article

References (60)

1. Governale, L. Methadone utilization in the US 2002-2006, FDA Center for Drug Evaluation and Research, 2007 .
2. Sims, S.A., Snow, L.A. & Porucznik, C.A. Surveillance of methadone-related adverse drug events using multiple public health data sources. J. Biomed. Inform. 40, 382-389 (2007). (Pubitemid 47187788)
3. US Government Accountability Office. Methadone-associated overdose deaths: Factors contributing to increased deaths and efforts to prevent them. Report GAO-09-341 (2009).
4. Eap, C.B., Buclin, T. & Baumann, P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin. Pharmacokinet. 41, 1153-1193 (2002). (Pubitemid 35398691)
5. Ferrari, A., Coccia, C.P., Bertolini, A. & Sternieri, E. Methadone-metabolism, pharmacokinetics and interactions. Pharmacol. Res. 50, 551-559 (2004).
6. Gruber, V.A. & McCance-Katz, E.F. Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Curr. HIV/AIDS Rep. 7, 152-160 (2010).
7. Saber-Tehrani, A.S., Bruce, R.D. & Altice, F.L. Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. Am. J. Drug Alcohol Abuse 37, 1-11 (2011).
8. Kharasch, E.D., Hoffer, C., Whittington, D. & Sheffels, P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin. Pharmacol. Ther. 76, 250-269 (2004). (Pubitemid 39221799)
9. Lu, W.J., Bies, R., Kamden, L.K., Desta, Z. & Flockhart, D.A. Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase). Drug Metab. Dispos. 38, 1308-1313 (2010).
10. Iribarne, C. et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem. Res. Toxicol. 9, 365-373 (1996). (Pubitemid 26079977)
11. Moody, D.E., Alburges, M.E., Parker, R.J., Collins, J.M. & Strong, J.M. The involvement of cytochrome P450 3A4 in the N-demethylation of L-alphaacetylmethadol (LAAM), norLAAM, and methadone. Drug Metab. Dispos. 25, 1347-1353 (1997). (Pubitemid 28010919)
12. Gerber, J.G., Rhodes, R.J. & Gal, J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16, 36-44 (2004). (Pubitemid 37532283)
13. Totah, R.A., Allen, K.E., Sheffels, P., Whittington, D. & Kharasch, E.D. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J. Pharmacol. Exp. Ther. 321, 389-399 (2007). (Pubitemid 46456979)
14. Totah, R.A., Sheffels, P., Roberts, T., Whittington, D., Thummel, K. & Kharasch, E.D. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108, 363-374 (2008). (Pubitemid 351304229)
15. Chang, Y., Fang, W.B., Lin, S.N. & Moody, D.E. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic Clin. Pharmacol. Toxicol. 108, 55-62 (2011).
16. Thompson, S.J., Koszdin, K. & Bernards, C.M. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 92, 1392-1399 (2000). (Pubitemid 30257201)
17. Wang, J.S., Ruan, Y., Taylor, R.M., Donovan, J.L., Markowitz, J.S. & DeVane, C.L. Brain penetration of methadone (R)-and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology (Berl.) 173, 132-138 (2004). (Pubitemid 38591157)
18. Bauer, B. et al. In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol. Pharmacol. 70, 1212-1219 (2006). (Pubitemid 44435972)
19. Ortega, I., Rodriguez, M., Suarez, E., Perez-Ruixo, J.J. & Calvo, R. Modeling methadone pharmacokinetics in rats in presence of P-glycoprotein inhibitor valspodar. Pharm. Res. 24, 1299-1308 (2007). (Pubitemid 46870595)
20. Maggiolo, F. Efavirenz: a decade of clinical experience in the treatment of HIV. J. Antimicrob. Chemother. 64, 910-928 (2009).
21. Rakhmanina, N.Y. & van den Anker, J.N. Efavirenz in the therapy of HIV infection. Expert Opin. Drug Metab. Toxicol. 6, 95-103 (2010).
22. Barrett, J.S., Joshi, A.S., Chai, M., Ludden, T.M., Fiske, W.D. & Pieniaszek, H.J. Jr. Population pharmacokinetic meta-analysis with efavirenz. Int. J. Clin. Pharmacol. Ther. 40, 507-519 (2002). (Pubitemid 35331935)
23. Zhu, M., Kaul, S., Nandy, P., Grasela, D.M. & Pfister, M. Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. Antimicrob. Agents Chemother. 53, 2346-2353 (2009).
24. Ngaimisi, E. et al. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin. Pharmacol. Ther. 88, 676-684 (2010).
25. Smith, P.F., DiCenzo, R. & Morse, G.D. Clinical pharmacokinetics of nonnucleoside reverse transcriptase inhibitors. Clin. Pharmacokinet. 40, 893-905 (2001). (Pubitemid 34066687)
26. Mouly, S. et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin. Pharmacol. Ther. 72, 1-9 (2002). (Pubitemid 34833182)
27. Fellay, J. et al. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur. J. Clin. Pharmacol. 60, 865-873 (2005). (Pubitemid 40386157)
28. Robertson, S.M., Maldarelli, F., Natarajan, V., Formentini, E., Alfaro, R.M. & Penzak, S.R. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J. Acquir. Immune Defic. Syndr. 49, 513-519 (2008).
29. Hariparsad, N., Nallani, S.C., Sane, R.S., Buckley, D.J., Buckley, A.R. & Desai, P.B. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J. Clin. Pharmacol. 44, 1273-1281 (2004). (Pubitemid 39391486)
30. Svärd, J., Spiers, J.P., Mulcahy, F. & Hennessy, M. Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans. J. Acquir. Immune Defic. Syndr. 55, 536-549 (2010).
31. Weiss, J., Herzog, M., König, S., Storch, C.H., Ketabi-Kiyanvash, N. & Haefeli, W.E. Induction of multiple drug transporters by efavirenz. J. Pharmacol. Sci. 109, 242-250 (2009).
32. Störmer, E., von Moltke, L.L., Perloff, M.D. & Greenblatt, D.J. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm. Res. 19, 1038-1045 (2002). (Pubitemid 34804248)
33. Weiss, J., Theile, D., Ketabi-Kiyanvash, N., Lindenmaier, H. & Haefeli, W.E. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab. Dispos. 35, 340-344 (2007). (Pubitemid 46333919)
34. Storch, C.H., Theile, D., Lindenmaier, H., Haefeli, W.E. & Weiss, J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem. Pharmacol. 73, 1573-1581 (2007). (Pubitemid 46527547)
35. Bousquet, L., Pruvost, A., Guyot, A.C., Farinotti, R. & Mabondzo, A. Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation. Antimicrob. Agents Chemother. 53, 896-902 (2009).
36. Marzolini, C., Troillet, N., Telenti, A., Baumann, P., Decosterd, L.A. & Eap, C.B. Efavirenz decreases methadone blood concentrations. AIDS 14, 1291-1292 (2000). (Pubitemid 30420682)
37. Clarke, S.M. et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br. J. Clin. Pharmacol. 51, 213-217 (2001). (Pubitemid 32391497)
38. McCance-Katz, E.F., Gourevitch, M.N., Arnsten, J., Sarlo, J., Rainey, P. & Jatlow, P. Modified directly observed therapy (MDOT) for injection drug users with HIV disease. Am. J. Addict. 11, 271-278 (2002). (Pubitemid 35332504)
39. Kharasch, E.D., Bedynek, P.S., Park, S., Whittington, D., Walker, A. & Hoffer, C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clin. Pharmacol. Ther. 84, 497-505 (2008).
40. Kharasch, E.D., Walker, A., Whittington, D., Hoffer, C. & Bedynek, P.S. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend. 101, 158-168 (2009).
41. Kharasch, E.D., Hoffer, C., Whittington, D., Walker, A. & Bedynek, P.S. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. Anesthesiology 110, 660-672 (2009).
42. Kharasch, E.D., Walker, A., Hoffer, C. & Sheffels, P. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin. Pharmacol. Ther. 76, 452-466 (2004). (Pubitemid 39469869)
43. Kharasch, E.D. et al. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin. Pharmacol. Ther. 82, 410-426 (2007). (Pubitemid 47414348)
44. Cvetkovic, M., Leake, B., Fromm, M.F., Wilkinson, G.R. & Kim, R.B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27, 866-871 (1999). (Pubitemid 29347585)
45. Kharasch, E.D., Francis, A., London, A., Frey, K., Kim, T. & Blood, J. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction. Clin. Pharmacol. Ther. 90, 100-108 (2011).
46. Ohnhaus, E.E., Breckenridge, A.M. & Park, B.K. Urinary excretion of 6 betahydroxycortisol and the time course measurement of enzyme induction in man. Eur. J. Clin. Pharmacol. 36, 39-46 (1989). (Pubitemid 19052008)
47. van de Kerkhof, E.G., de Graaf, I.A., Ungell, A.L. & Groothuis, G.M. Induction of metabolism and transport in human intestine: validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vitro. Drug Metab Dispos 36, 604-613 (2008). (Pubitemid 351397987)
48. Faucette, S.R. et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J. Pharmacol. Exp. Ther. 320, 72-80 (2007). (Pubitemid 46025721)
49. Zhang, J.G., Ho, T., Callendrello, A.L., Crespi, C.L. & Stresser, D.M. A multi-endpoint evaluation of cytochrome P450 1A2, 2B6 and 3A4 induction response in human hepatocyte cultures after treatment with ß- naphthoflavone, phenobarbital and rifampicin. Drug Metab. Lett. 4, 185-194 (2010).
50. Bailey, D.G., Dresser, G.K., Leake, B.F. & Kim, R.B. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin. Pharmacol. Ther. 81, 495-502 (2007). (Pubitemid 46452308)
51. Matsushima, S. et al. Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol. Pharmacol. 73, 1474-1483 (2008). (Pubitemid 351574837)
52. Swift, B., Tian, X. & Brouwer, K.L. Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function. Pharm. Res. 26, 1942-1951 (2009).
53. Cui, X., Thomas, A., Gerlach, V., White, R.E., Morrison, R.A. & Cheng, K.C. Application and interpretation of hPXR screening data: Validation of reporter signal requirements for prediction of clinically relevant CYP3A4 inducers. Biochem. Pharmacol. 76, 680-689 (2008).
54. Esteban, J. et al. Increase of R-/S-methadone enantiomer concentration ratio in serum of patients treated with either nevirapine or efavirenz. Drug Metab. Lett. 2, 269-279 (2008).
55. Crettol, S. et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin. Pharmacol. Ther. 78, 593-604 (2005). (Pubitemid 41773635)
56. Crettol, S. et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin. Pharmacol. Ther. 80, 668-681 (2006). (Pubitemid 44920225)
57. Roxane Laboratories. Dolophine hydrochloride CII prescribing information . Accessed 29 May 2011.
58. Jeong, S., Nguyen, P.D. & Desta, Z. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob. Agents Chemother. 53, 541-551 (2009).
59. Crettol, S. et al. No influence of ABCB1 haplotypes on methadone dosage requirement. Clin. Pharmacol. Ther. 83, 668-669; author reply 669 (2008).
60. Dirson, G. et al. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier. Pharm. Res. 23, 1525-1532 (2006). (Pubitemid 43993816)